Relugolix
| Relugolix | |
|---|---|
| Term | Relugolix |
| Short definition | relugolix - (pronounced) (reh-loo-GOH-lix) drug used to treat adults with advanced prostate cancer. Relugolix binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland, preventing the pituitary gland from making the hormones follicle-stimulating hormone (FSH) and luteinizing hormone (LH). |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
relugolix - (pronounced) (reh-loo-GOH-lix) drug used to treat adults with advanced prostate cancer. Relugolix binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland, preventing the pituitary gland from making the hormones follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This causes the testicles to stop producing testosterone. Relugolix can stop the growth of cancer cells that need testosterone to grow. It's a type of GnRH antagonist. Also called Orgovyx
External links
- Medical encyclopedia article on Relugolix
- Wikipedia's article - Relugolix
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski